Vicadrostat

DRUG5 trials

Sponsors

Boehringer Ingelheim

Conditions

Cardiovascular DiseasesChronic Kidney DiseaseDiabetes Mellitus, Type 2HealthyHeart FailureHypertension

Phase 1

A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together

CompletedNCT07035457

Boehringer IngelheimHealthy

Start: 2025-07-02End: 2025-08-15Updated: 2025-08-20

Phase 2

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

Active, not recruitingNCT06926660

Boehringer IngelheimChronic Kidney Disease

Start: 2025-07-18End: 2026-08-20Target: 416Updated: 2026-04-02

Phase 3

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

RecruitingNCT06424288

Boehringer IngelheimHeart Failure

Start: 2024-06-17End: 2028-05-22Target: 6000Updated: 2026-04-02

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

RecruitingNCT06935370

Boehringer IngelheimHeart Failure

Start: 2025-05-20End: 2029-02-22Target: 4200Updated: 2026-04-02

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

RecruitingNCT07064473

Boehringer IngelheimCardiovascular Diseases, Diabetes Mellitus, Type 2, Hypertension

Start: 2025-05-09End: 2029-12-21Target: 11800Updated: 2026-04-02

Related Papers

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper

ESC Heart Failure2025-05-193 citations